Testing a new medication for muscle weakness in adults over 45

This trial is testing whether ruxolitinib, a medication that blocks a specific immune pathway in the body, can slow or improve muscle weakness caused by inclusion body myositis (IBM). IBM is a rare condition where the immune system and muscle degeneration combine to cause progressive weakness, especially in older adults. Researchers believe this medication might work by stopping the immune damage that worsens the disease.

Inclusion body myositis is very hard to treat with current therapies, and most patients continue to get weaker over time, losing their independence and quality of life. This medication offers a new approach by targeting a specific immune signal that researchers have found is unusually active in IBM muscles.